A circulating factor V inhibitor: possible side effect of treatment with streptomycin.
A potent inhibitor of factor V was discovered in a middle aged woman shortly after streptomycin therapy. The patient suffered from severe bleeding over a period of 10 days and the inhibitor was demonstrable for 6 weeks. By use of specific antisera the anticoagulant was found to be of an IgG nature. In agar electrophoresis the inhibitor mowed with the immunoglobulin fraction and was separable from factor V activity in the pathological plasma although no factor V activity was demonstrable in untreated patient plasma. It is suggested that this method should be used to distinguish between cases of inhibitors in patients with congenital factor V deficiency and cases of transient inhibitors in patients with normal factor V production.
D000925:Anticoagulants; D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000209:etiology*; D003937:Diagnosis, Differential; D005165:Factor V / Q000037:antagonists & inhibitors*; D005166:Factor V Deficiency / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008875:Middle Aged; D013307:Streptomycin / Q000009:adverse effects* / Q000627:therapeutic use; D013530:Surgical Wound Infection / Q000188:drug therapy
D000925:Anticoagulants; D007074:Immunoglobulin G; D005165:Factor V; D013307:Streptomycin